Dutogliptin

Dutogliptin is an orally available, potent, and selective dipeptidyl peptidase-4 (DPP4) inhibitor.

Signaling Pathways >> Metabolic Enzyme/Protease >> Dipeptidyl Peptidase

Research Areas >> Metabolic Disease

DPP4[1]

Dutogliptin is highly water soluble (>2000 mg/mL), has low cellular permeability, exhibits low plasma protein binding (11%) and is rapidly absorbed with a Tmax of 3-4 h and a half-life of 10-13 h. The compound is metabolically stable and does not inhibit or induce the activity of major CYP450s[2].

[1]. Marier JF, et al. Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase-4 inhibitor. Clin Pharmacol Drug Dev. 2014 Jul;3(4):297-304.

[2]. Pattzi HM, et al. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55.

Talabostat mesylate | Linagliptin | Teneligliptin | Vildagliptin (LAF-237) | AZD7986 | Omarigliptin | Anagliptin | Trelagliptin | Gemigliptin | DPP-IV-IN-2 | DBPR108 | Diprotin A TFA (Ile-Pro-Pro (TFA)) | Saikogenin A | UAMC 00039 dihydrochloride | Gosogliptin